Clinical Trials
85 trialsCarmustine, Etoposide, Cyclophosphamide, and Stem Cell Transplant in Treating Patients With HIV-Associated Lymphoma
City of Hope Medical Center
Lifileucel With Reduced Dose Fludarabine/Cyclophosphamide Lymphodepletion and Interleukin-2 for the Treatment of Patients With Unresectable or Metastatic Melanoma
University of Kansas Medical Center
A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies
Thomas Jefferson University
Proof of Concept of TBio-4101, Lymphodepleting Chemo, IL-2 for Relapsed/Refractory Melanoma
H. Lee Moffitt Cancer Center and Research Institute
PALANGI3
Centre Oscar Lambret
Vemurafenib With Lymphodepletion Plus Adoptive Cell Transfer & High Dose IL-2 Metastatic Melanoma
H. Lee Moffitt Cancer Center and Research Institute
Lymphodepletion Plus Adoptive Cell Transfer With High Dose IL-2 in Patients With Metastatic Melanoma
H. Lee Moffitt Cancer Center and Research Institute
Prospective Randomized Study of Cell Transfer Therapy for Metastatic Melanoma Using Tumor Infiltrating Lymphocytes Plus IL-2 Following Non-Myeloablative Lymphocyte Depleting Chemo Regimen Alone or in Conjunction With 12Gy Total Body Irradiation (TBI...
National Institutes of Health Clinical Center (CC)
Ipilimumab With Lymphodepletion Plus Adoptive Cell Transfer and High Dose IL-2 in Melanoma Mets Pts
H. Lee Moffitt Cancer Center and Research Institute
Combining PD-1 Blockade, CD137 Agonism and Adoptive Cell Therapy for Metastatic Melanoma
H. Lee Moffitt Cancer Center and Research Institute
Dendritic Cells (White Blood Cells) Vaccination for Advanced Melanoma
University of Pennsylvania
TIL
The Netherlands Cancer Institute
Pixatimod (PG545) Plus Nivolumab in PD-1 Relapsed/Refractory Metastatic Melanoma and NSCLC and With Nivolumab and Low-dose Cyclophosphamide in MSS Metastatic Colorectal Carcinoma (mCRC)
University of Pittsburgh
TIL-ACT After NMA Chemo with IL-2 and Nivo Rescue in Metastatic Melanoma (mMEL)
Centre Hospitalier Universitaire Vaudois
Pembrolizumab, Standard Chemotherapy, Tumor Infiltrating Lymphocytes, and High- or Low-Dose Aldesleukin in Treating Patients With Metastatic Melanoma
M.D. Anderson Cancer Center
Dendritic Cell Vaccination in Patients With Advanced Melanoma
University of Pennsylvania
Genetically Modified Therapeutic Autologous Lymphocytes Followed by Aldesleukin in Treating Patients With Stage III or Metastatic Melanoma
M.D. Anderson Cancer Center
CD8+ Antigen-Specific T Cells, Cyclophosphamide, Aldesleukin, and Ipilimumab in Treating Patients With Metastatic Melanoma
M.D. Anderson Cancer Center
AlloHCT From Matched Unrelated Donors in Pts w/ Advanced Hematologic Malignancies & Disorders
City of Hope Medical Center
A Phase I Trial of T Cells Expressing an Anti-GD2 Chimeric Antigen Receptor in Children and Young Adults With GD2+ Solid Tumors
National Institutes of Health Clinical Center (CC)
Busulfan, Cyclophosphamide, & Antithymocyte Globulin Followed by Stem Cell Transplant in Treating Hematologic Cancer
University of Nebraska
FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors
Fate Therapeutics
Treatment of Advanced Solid Tumors With TSA-CTL(Tumor Specific Antigen-Induced Cytotoxic T Lymphocytes)
BGI, China
Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Melanoma
National Institutes of Health Clinical Center (CC)
Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed, Non-metastatic Desmoplastic Medulloblastoma
Children's Oncology Group
Tumor-Infiltrating Lymphocytes After Combination Chemotherapy in Treating Patients With Metastatic Melanoma
Fred Hutchinson Cancer Center
Study of NY-ESO-1 ISCOMATRIX® in Patients With Measurable Stage III or IV Melanoma
Ludwig Institute for Cancer Research
T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-DP0401 Positive
National Institutes of Health Clinical Center (CC)
Phase 1 Trial of Siplizumab and Dose-Adjusted EPOCH-Rituximab in T- and NK-Cell Lymphomas
National Institutes of Health Clinical Center (CC)
Combination Chemotherapy and Donor Stem Cell Transplant in Treating Patients With Aplastic Anemia or Hematologic Cancer
Roswell Park Cancer Institute
Investigator Initiated Phase 1 Study of TBI-1201
Mie University
High-Dose Chemotherapy With or Without Total-Body Irradiation Followed by Autologous Stem Cell Transplant in Treating Patients With Hematologic Cancer or Solid Tumors
Roswell Park Cancer Institute
Vaccine Therapy With or Without Cyclophosphamide in Treating Patients Who Have Undergone Surgery for Stage II, Stage III, or Stage IV Melanoma
University of Virginia
T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Cancer
National Institutes of Health Clinical Center (CC)
ACTIVATE
University Health Network, Toronto
Ultraviolet-B Light Therapy and Allogeneic Stem Cell Transplantation in Treating Patients With Hematologic Malignancies
Case Comprehensive Cancer Center
Vemurafenib and TIL Therapy for Metastatic Melanoma
Herlev Hospital
Peginterferon and TIL Therapy for Metastatic Melanoma
Herlev Hospital
Tumor-Infiltrating Lymphocytes And Low-Dose Interleukin-2 Therapy Following Cyclophosphamide And Fludarabine In Patients With Melanoma
University Health Network, Toronto
Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies
Case Comprehensive Cancer Center
Chemotherapy, Radiation Therapy, and Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer
M.D. Anderson Cancer Center
Cyclophosphamide and Fludarabine Followed By Interleukin-2 Gene-Modified Tumor Infiltrating Lymphocytes in Treating Patients With Metastatic Melanoma
National Institutes of Health Clinical Center (CC)
Rasburicase in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer or Other Disease Undergoing Donor Stem Cell Transplant
Massachusetts General Hospital
Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies
Fred Hutchinson Cancer Center
Haploidentical Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancer
Fred Hutchinson Cancer Center
Laboratory-Treated T Cells and Ipilimumab in Treating Patients With Metastatic Melanoma
Fred Hutchinson Cancer Center
Laboratory-Treated T Cells and Aldesleukin After Cyclophosphamide in Treating Patients With Stage IV Melanoma
Fred Hutchinson Cancer Center
Safety Study of a Melanoma Vaccine (GVAX) With or Without Cyclophosphamide in Patients With Surgically Resected Melanoma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Aprepitant, Granisetron, & Dexamethasone in Preventing Nausea & Vomiting in Pts. Receiving Cyclophosphamide Before a Stem Cell Transplant
Barbara Ann Karmanos Cancer Institute
Cyclophosphamide, Fludarabine, and Total-Body Irradiation Followed By Cellular Adoptive Immunotherapy, Autologous Stem Cell Transplantation, and Interleukin-2 in Treating Patients With Metastatic Melanoma
National Institutes of Health Clinical Center (CC)